In this episode, I had the great pleasure of catching up with Roger Wyse, Founder and Managing Partner at Spruce Capital Partners. I have had the pleasure of collaborating with Roger over the past decade (or more) and have always found his insights of great value and was delighted to have the chance to discuss his experiences and learnings.

Roger reflected on his early experiences at Burrill and the opportunities and challenges of being the first biobased economy venture fund. He then looked back on the early syndication efforts in building the fund and the journey to establishing Spruce Capital Partners in 2013. Spruce was seeking true disruptors, yet in bioeconomy, disruption is an oxymoron! Producers are conservative as they notionally have '40 shots on goal' (i.e. 40 growing seasons) and industrial biotech is conservative as consumer facing companies have brands to protect. We also reflected on the motivations and time horizons associated with different limited partners.

We discussed time associated with the market forming actions from regulators, such as sustainable aviation fuels (SAF) and market constraining actions from (same) regulators in securing approvals to construct processing plants or introducing technologies to market. Roger noted that in terms of time, society now has a 100-year environmental debt that we need to start to pay off!

It came to light that the technology transfer process from research institution to commercial partner in the US and Australian systems have eerie similarities! IP valuation disparities and divergent incentives amongst the parties can make alignment and deal finalisation time consuming. We speculated that this may in fact be the first of the 'valleys of death' that a licensee or venture might face!

Roger co-authored a discussion paper  Building a Robust Bioeconomy: A Statement of Concern and Call to Action in October 2023, which explores the convergence of enabling technologies to accelerate the concept to commercialisation process. Reducing the time to market requires market, product and development processes to be undertaken in parallel, rather than the near linear fashion they are today. This requires patient capital alongside a systematic engagement across the stakeholders (or value pool participants). Roger also noted that there are process engineering expertise and infrastructure challenges to support scaleup and bridging product to market challenges.